Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715954 | 1.00 | USP2 (0.54) | USP2ALDH1A1ANPEPKEAP1SMN1; SMN2 | |
| SCHEMBL39809 | 1.00 | USP2 (0.54) | USP2ALDH1A1ANPEPKEAP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2383770 | 0.98 | ALDH1A1 (0.55) | USP2ALDH1A1ANPEPKEAP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2187515 | 0.98 | ALDH1A1 (0.55) | USP2ALDH1A1ANPEPKEAP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2187508 | 0.98 | ALDH1A1 (0.55) | USP2ALDH1A1ANPEPKEAP1SMN1; SMN2 | |
| SCHEMBL9547004 | 0.83 | USP2 (0.47) | USP2ALDH1A1ANPEPKEAP1SMN1; SMN2 | |
| SCHEMBL6680924 | 0.82 | — | — | |
| SCHEMBL1043849 | 0.82 | PIK3CD (0.39) | ALDH1A1ANPEPKDM4EMEN1KMT2A | |
| SCHEMBL17828102 | 0.80 | USP2 (0.58) | USP2ALDH1A1ANPEPKEAP1SMN1; SMN2 | |
| SCHEMBL372508 | 0.80 | USP2 (0.58) | USP2ALDH1A1ANPEPKEAP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | claimed |
| EP-2262766-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2010-12-22 | — | — | EP | claimed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| EP-3345917-B1 | ANTIPROTOZOAL COMPOUNDS | BACOBA AG (CH) | 2021-11-17 | — | — | EP | disclosed |
| EP-3345917-B1 | ANTIPROTOZOAL COMPOUNDS | BACOBA AG (CH) | 2021-11-17 | — | — | EP | disclosed |
| EP-3877356-A1 | BICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-2981535-B1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | TOPIVERT PHARMA LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-10435361-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-01 | — | — | US | disclosed |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| EP-3345917-A1 | ANTIPROTOZOAL COMPOUNDS | Bacoba AG (CH) | 2018-07-11 | — | — | EP | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| WO-2009077366-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20080132494-A1 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | USP2 3376/4885ALDH1A1 2409/4885ANPEP 1995/4885 |
| US-20090163499-A1 | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX1 | USP2 3032/4885ALDH1A1 2011/4885ANPEP 1977/4885 |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | P2RX2, P2RX3, TPX2 | USP2 1386/4885ALDH1A1 4311/4885ANPEP 2608/4885 |
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | USP2 4195/4885ALDH1A1 1946/4885ANPEP 1666/4885 |
| US-20190231787-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | ADH1A, NTRK2, ADH1C | USP2 2823/4885ALDH1A1 82/4885ANPEP 2825/4885 |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | USP2 3774/4885ALDH1A1 2036/4885ANPEP 1607/4885 |
| US-20080132494-A1 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX1 | USP2 3626/4885ALDH1A1 947/4885ANPEP 2756/4885 |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX5 | USP2 3539/4885ALDH1A1 2080/4885ANPEP 1659/4885 |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | IL1B, ADORA2B, AVPR1B | USP2 4398/4885ALDH1A1 1016/4885ANPEP 2779/4885 |
| US-10435361-B2 | Kinase inhibitors | SYK, LYN, BTK | USP2 3447/4885ALDH1A1 4408/4885ANPEP 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.